Pomdoctor Ltd ADR Dossier - Source-backed chat

Pomdoctor Ltd ADR

POMNASDAQ

SectorHealth Care

IndustryDrug Retail

Beta (adjusted)0.89

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.92Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $8.5M

Enterprise Value $18.9M

Shares Outstanding 9.7M diluted

Next Earnings Date3 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

POMDOCTOR Ltd is facing severe operational, financial, and regulatory headwinds that threaten its viability as a going concern. Despite achieving 16.7% year-over-year revenue growth in FY2025 (reaching RMB 399.9 million), the company's net loss widened dramatically by 250% to RMB 130.9 million, driven by a 328.5% surge in R&D expenses and heavy IPO-related costs. With only RMB 9.6 million in cash against RMB 113.2 million in net current liabilities, the company has a critically short liquidity runway. Furthermore, the stock has plummeted over 98% from its IPO price, triggering a Nasdaq delisting warning for trading below $1.00. While the upcoming 1-for-18 reverse ADS split on June 22, 2026, may temporarily resolve the bid price deficiency, it does not address the underlying cash burn or the overhang from active securities class-action lawsuits alleging an illicit pump-and-dump scheme.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.0130%

The company fails to secure additional financing, leading to a severe liquidity crunch that disrupts its pharmaceutical supply chain and internet hospital operations. Active class-action lawsuits result in substantial legal liabilities, and the company is ultimately delisted from Nasdaq due to failure to maintain listing standards or filing delays, forcing a restructuring or liquidation.

Base CaseCentral scenario

$0.0855%

POMDOCTOR implements its 1-for-18 reverse ADS split on June 22, 2026, successfully regaining compliance with Nasdaq's minimum bid price rule. However, operational cash burn remains high, and the company is forced to seek highly dilutive equity or debt financing to address its RMB 113.2 million net current liability position. Revenue growth continues at a moderate double-digit pace, but profitability remains elusive due to intense competition in China's digital healthcare market.

Bull CaseUpside scenario

$1.8015%

The company successfully transitions its business model toward high-margin 'AI + Medical-Grade Smart Wearables' for full-cycle chronic disease management, reducing reliance on low-margin pharmaceutical wholesale. Strategic partnerships with major pharmaceutical manufacturers and expanded integration with online medical insurance across major Chinese cities accelerate user monetization, driving the company to operating cash flow break-even by late 2027.

Scenarios reflect our research view at the research date.

Key Investment Merits

Established network of over 212,800 contracted doctors and nearly 700,000 transacting patients in China's chronic disease management sector.
Strategic pivot toward 'AI + Medical-Grade Smart Wearables' to build a higher-margin, closed-loop healthcare ecosystem.
Integration with online medical insurance across major Chinese cities, enhancing platform accessibility and patient stickiness.

Key Investment Risks

Severe going-concern risk with net current liabilities of RMB 113.2 million and cash of only RMB 9.6 million as of year-end 2025.
Massive operating cash burn of RMB 148.5 million in FY2025, rapidly consuming IPO proceeds.
Overhang from multiple securities class-action lawsuits alleging stock promotion and pump-and-dump schemes following the October 2025 IPO.
Regulatory and operational risks associated with the Variable Interest Entity (VIE) structure in China.

Thesis Invalidation Triggers

Securing a major strategic investment or long-term debt facility that fully funds the working capital deficit.
A faster-than-expected path to profitability driven by rapid adoption of the AI smart wearables ecosystem.
Favorable dismissal or settlement of all outstanding class-action litigation with minimal financial impact.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.